BIOLOGY 2F03 Chapter Notes - Chapter 7-8: Bortezomib, Cytopenia, Hematologic Disease
20 May 2018
School
Department
Course
Professor
1. Other drugs in MM
• Proteasome inhibitors
o Proteasomes degrade Ikb = free Nfkb = transcription
o The end point of the RANKl pathway of osteoclast activation is Nfkb
o Bortezomib bind to the chymotryptic site in the core of the proteasome to inhibit
it
o Bortezomib increases bone marrow density
• Monoclonal Antibodies
o Denosumab (anti-RANKl) leads to osteoclast apoptosis and prevents skeletal-
related-events but increases risk of death compared to zoledronic acid
o Anti-Dkk1 antibodies lead to bone formation in mice
• Novel anabolic agents eg BHq880, sotatercept
2.43 - MYELODYSPLASTIC SYNDROMES
1. Recap of clinical features of MDS
D - heterogeneous haematological disorders characterised by ineffective clonal
haematopoiesis, peripheral cytopenias and hypercellular BM.
I
A - 70-75years
S
G
A - previous chemo/radio are risk factors
P
C - cytopenias = anaemia, thrombocytopenia, neutropenia
find more resources at oneclass.com
find more resources at oneclass.com
